Cargando…
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
BACKGROUND: There is increased recognition that cancers of the upper GI tract comprise distinct epidemiological and molecular entities. Erlotinib has shown activity in patients with adenocarcinoma of the oesophagus/gastro-oesophageal junction (GEJ), but not in distal gastric cancer. mFOLFOX6 is one...
Autores principales: | Wainberg, Z A, Lin, L-S, DiCarlo, B, Dao, K M, Patel, R, Park, D J, Wang, H-J, Elashoff, R, Ryba, N, Hecht, J R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171005/ https://www.ncbi.nlm.nih.gov/pubmed/21811258 http://dx.doi.org/10.1038/bjc.2011.280 |
Ejemplares similares
-
Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction
por: Grillo, Federica, et al.
Publicado: (2020) -
Adenocarcinoma of oesophagus involving gastro-oesophageal junction following mini-gastric bypass/ one anastomosis gastric bypass
por: Aggarwal, Sandeep, et al.
Publicado: (2020) -
Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014) -
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
por: Birkman, Eva-Maria, et al.
Publicado: (2016) -
Stenting as a palliative method in the management of advanced squamous cell carcinoma of the oesophagus and gastro-oesophageal junction
por: Wlodarczyk, Janusz, et al.
Publicado: (2016)